Clinical trial · Nutrition · 14 Nov 2026
In 27 adults with ulcerative colitis, an oral microbiota product lined up with lower symptom scores than placebo
Source: Inflammatory Bowel Diseases
What the research found
A single-center randomized double-blind placebo-controlled pilot was published online on 14 November 2026. Adults with ulcerative colitis and an endoscopic Mayo score of at least 1 took a standardized oral lyophilized microbiota product or placebo for 8 weeks. Gut samples were sequenced from stool. The microbiota group (n=13) had higher donor engraftment at every measured week than placebo (n=14). Partial Mayo scores were lower than baseline at weeks 4 and 8 in the microbiota group. Placebo scores did not change clearly. Donor engraftment did not correlate with the symptom score or with clinical response. Engrafting taxa did not form a clear pattern in people who met a week-4 response line. Registry NCT03948919. A pilot. The abstract does not give age or sex. DOI 10.1093/ibd/izag236. Not medical advice.
Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.
More nutrition news
- In 32 young adults, four weeks of watermelon lined up with a lower TMAO reading inside that period
- In 326 older adults, two years of a walnut diet had little effect on body fat
- In 21,734 adults, numbing and spicy foods lined up with lower cardiovascular disease rates
- In 10 adults with obesity, a food-based very-low-energy plan was feasible for 8 weeks
- In 100 Bangkok store workers, night shifts lined up with a less varied diet